Skip to main content
Premium Trial:

Request an Annual Quote

Bye-Bye PE, Hello Applera

NEW YORK, Nov 28 – It’s official. As of Thursday, PE Corp., the parent company of Applied Biosystems and Celera Genomics, will take on its new name, Applera—a combination of the names of the company's two operating businesses.

The PE Biosystems name change to Applied Biosystems will also become effective on November 30, and its stock symbol on the New York Stock Exchange (NYSE) will change from PEB to ABI at the opening of trading on that date. The NYSE symbol for Celera will remain CRA.

Applera will also have a new Web address, www.applera.com effective November 30.

Tony White, chairman, president, and CEO of the company, said in a statement that the name change symbolizes the company’s intention to capitalize on the synergies of the two groups in pursuing a molecular diagnostics initiative.

The more likely reason for the change, though, is to dissociate the company from the Perkin-Elmer name, which the company dumped together with its analytical instruments division.

Stockholders approved the name changes at the company's annual meeting on October 19.

Applied Biosystems, based in Foster City, Calif., develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. The unit reported sales of $1.4 billion during fiscal 2000.

Celera, based in Rockville, Md., is in the business of genomic databases. The unit reported revenues of $18.3 million in its most recent quarter with a net loss of $25.7 million.
The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more